Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 18Keratosis 3Condylomata Acuminata 3Carcinoma, Basal Cell 3Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Glioblastoma 2Warts 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Sialorrhea 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Atypical Squamous Cells of the Cervix 1Adenocarcinoma 1

Interventions

Restraint, Physical 2Human Papillomavirus DNA Tests 2Colposcopy 2epigallocatechin gallate 1Imiquimod 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Atypical Squamous Cells of the Cervix × Imiquimod × Clear all
NCT02689726 2016-12-02

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

Genticel

Phase 1 Terminated
13 enrolled

Atypical Squamous Cells of the Cervix

Data powered by HemOnc (CC BY 4.0) Colophon âš¡